<DOC>
	<DOCNO>NCT01874145</DOCNO>
	<brief_summary>This open-label , randomize , multi-center , parallel-arm study ass safety tolerability daily dose Glatiramer Acetate ( GA ) 40 mg/mL three time week ( TIW ) administer subcutaneously ( SC ) compare GA 20 mg/mL every day ( QD ) administer SC .</brief_summary>
	<brief_title>Safety Tolerability Glatiramer Acetate</brief_title>
	<detailed_description>The study comprise Core study Extension phase . During Core study , subject evaluate study site 5 schedule visit Months : -1 ( Screening ) , 0 ( Baseline ) , 1 , 2 , 4 ( Termination/Early Termination ) . Subjects complete schedule visit final procedure assessment perform final visit ( Month 4 , Termination visit ) . Subjects withdraw study complete 4 month evaluation period Early Termination ( ET ) procedures assessment perform final visit . During Extension phase , subject offer continue treatment GA 40 mg/mL TIW . Subjects evaluate every 4 month dose strength commercially available treatment Relapsing-Remitting Multiple Sclerosis ( RRMS ) patient development GA dose regimen stop Sponsor , last visit phase call Termination/ET-Extension visit .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Glatiramer Acetate</mesh_term>
	<criteria>1 . Men woman least 18 year age old 2 . Subjects must confirm documented RRMS diagnosis define Revised McDonald criterion , relapse onset disease relapsingremitting disease course 3 . Subjects must ambulatory Kurtzke Expanded Disability Status Scale ( EDSS ) score 05.5 Screening Baseline visit . 4 . Subjects must stable neurological condition , relapsefree free corticosteroid treatment [ intravenous ( IV ) , intramuscular ( IM ) and/or per o ( PO ) ] adrenocorticotrophic hormone ( ACTH ) , 60 day prior randomization . 5 . Subjects must treat Glatiramer Acetate ( GA ) 20mg/mL QD SC injection minimum 6 month prior screen . 6 . Women childbearing potential must practice acceptable method birth control [ acceptable method birth control study include : surgical sterilization , intrauterine device , oral contraceptive , contraceptive patch , longacting injectable contraceptive , partner 's vasectomy doublebarrier method ( condom diaphragm spermicide ) ] . 7 . Subjects must able sign date write informed consent prior enter study . 8 . Subjects must willing able comply protocol requirement duration study 1 . Subject contraindication Glatiramer Acetate therapy 2 . Subjects progressive form multiple sclerosis ( MS ) . 3 . Subjects Neuromyelitis Optica ( NMO ) . 4 . Use experimental investigational drug , and/or participation drug clinical study within 6 month prior screen . 5 . Concomitant use disease modify drug MS ( ( Fingolimod ( Gilenya® ) , dimethyl fumarate ( Tecfidera® ) , Teriflunomide ( Aubagio® ) intravenous immunoglobulin ( IVIG ) ) within 6 month prior screen 6 . Previous use mitoxantrone , cladribine , alemtuzumab , rituximab , natalizumab . 7 . Chronic ( 30 consecutive day ) systemic ( IV , PO IM ) corticosteroid treatment within 6 month prior screen visit . 8 . Previous total body irradiation total lymphoid irradiation . 9 . Previous stemcell treatment , autologous bone marrow transplantation allogenic bone marrow transplantation . 10 . Pregnancy breastfeed . 11 . Subjects clinically significant unstable medical surgical condition would preclude safe complete study participation , determine medical history , physical exam , ECG abnormal laboratory test . Such condition may include hepatic , renal metabolic disease , systemic disease , acute infection , current malignancy recent history ( 5 year ) malignancy , major psychiatric disorder , history drug and/or alcohol abuse allergy could detrimental accord investigator 's judgment . 12 . Subjects underwent endovascular treatment Chronic Cerebrospinal Venous Insufficiency ( CCSVI ) . 13 . Employees clinical study site individual involve conduct study , immediate family member individual</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Relapsing-Remitting Multiple Sclerosis</keyword>
	<keyword>Glatiramer Acetate</keyword>
	<keyword>Glatiramer</keyword>
</DOC>